

**Date and Time:** *Thursday 6<sup>th</sup> June 2013*

**Minutes:** confirmed

**Guideline Development Group Meeting 6: Dyspepsia & GORD**

**Place:** NICE office, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

**Present:** Peter Barry (Chair) (PB)  
 John de Caestecker (JD)  
 Mimi McCord (MM)  
 Ann Harding (AH)  
 Clodna McNulty (CM)  
 Hugh Barr (HB)

**Apologies:** Mark Follows (MF) Ben Doak (BD)  
 Alex Ford (AF) Emma Banks (EB)  
 Janusz Jankowski (JJ)

<b>In attendance:</b> NICE Staff: Katy Harrison (KH) Emma McFarlane (EM) Gabriel Rogers (GR)	Victoria Thomas (VT) Rachel Houten (RH) Michael Heath (MH) Toni Tan (TT)	
--	---	--

**Observers:**

--	--	--

**Notes**

1. PB welcomed the group to the 6<sup>th</sup> meeting of this GDG. Apologies were received from MF, AF and JJ and no new conflicts of interest were declared. Minutes for the previous meeting were agreed.
2. VT talked to the group about a new project the public involvement programme at NICE is piloting with this guideline. A short *patient decision aid* will be developed to support the implementation of this guideline and GDG members were asked to volunteer to assist the development of this aid.
3. EM gave a presentation to the group looking at what H. pylori eradication regimens should be offered as second-line treatments when first-line treatments fail. The presentation included the PICO, the inclusion/exclusion criteria used and detailed the literature search.

## Notes

4. KH went on to present the outcomes for eradication rates, firstly explaining the evidence was analysed using a network meta analysis which is often used when there are multiple treatments for a decision problem and particularly useful when published studies are not available comparing each treatment of interest. As a result of this approach treatments can be ranked in terms of effectiveness. The group then discussed the information presented and evidence statements were reviewed and changes agreed.
5. RH presented a summary of the health economic evidence for this question. The group discussed the uncertainty of the cost effectiveness as this was driven by the uncertainty of which regimen is most effective.
6. The GDG discussed and agreed recommendations for the second-line treatments for H. pylori eradication regimes. Towards the end of the discussions, MM had to leave the meeting. The group was no longer quorate and so the discussions were stopped prematurely.
7. PB closed the meeting and thanked everyone for attending.

### **Date and venue of the next meeting:**

Next Meeting: 31<sup>st</sup> July 2013 at NICE office, City Tower, Piccadilly Plaza, Manchester, M1 4BD